Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium.

Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE

Original Publication: Malden, MA : WileyBlackwell Pub., 2008-

Neoplasm, Residual*/diagnosis ; Neoplasm, Residual*/blood ; Circulating Tumor DNA*/blood ; Circulating Tumor DNA*/genetics ; Neoplasms*/blood ; Neoplasms*/diagnosis ; Neoplasms*/genetics ; Biomarkers, Tumor*/blood ; Biomarkers, Tumor*/genetics; Humans ; Liquid Biopsy/methods

The use of a liquid biopsy to assess molecular residual disease (MRD) of solid tumors holds significant promise for improving outcomes for patients with cancer. Liquid biopsies are a minimally invasive approach for the identification of circulating tumor biomarkers through a simple blood sample. Assays capable of detecting MRD through analysis of circulating tumor DNA (ctDNA) are rapidly evolving for clinical study applications and therapeutic interventions. To address these opportunities, BLOODPAC-a multi-disciplinary consortium representing stakeholders from public, industry, academia, and regulatory agencies-formulated a lexicon that provides a shared framework and clear definitions using liquid biopsies for solid tumor MRD with an emphasis on ctDNA detection. The terms in the lexicon are categorized under general MRD, ctDNA testing methodologies, reporting results, and acquisition timepoints, including examples of current and potential clinical use cases for MRD tests. The overall goal is to provide a unified language and approaches to solid tumor MRD to advance applications of these technologies, allow data aggregation to strengthen future evidence, and facilitate regulatory approvals, leading to the use of liquid biopsy as an early endpoint in clinical trials. We believe that a common set of terminology and methods for solid tumor MRD can improve understanding and appropriate use of testing, accelerate clinical development, and improve outcomes for cancer patients.
(© 2025 The Author(s). Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)

Crit Rev Oncol Hematol. 2024 Feb;194:104242. (PMID: 38128627)
Blood. 2008 Dec 15;112(13):4808-17. (PMID: 19064740)
Nature. 2013 May 2;497(7447):108-12. (PMID: 23563269)
Sci Rep. 2023 Aug 19;13(1):13502. (PMID: 37598236)
Ann Oncol. 2021 Apr;32(4):466-477. (PMID: 33548389)
J Immunother Cancer. 2023 Feb;11(2):. (PMID: 36796877)
JCO Oncol Pract. 2024 Nov;20(11):1460-1470. (PMID: 39531841)
Front Oncol. 2022 Jul 20;12:943253. (PMID: 35936733)
Int J Cancer. 2022 May 1;150(9):1537-1548. (PMID: 34994972)
Cancers (Basel). 2023 Mar 03;15(5):. (PMID: 36900369)
Nat Commun. 2024 Aug 10;15(1):6862. (PMID: 39127745)
Ann Oncol. 2021 Feb;32(2):229-239. (PMID: 33232761)
Ann Oncol. 2022 Aug;33(8):750-768. (PMID: 35809752)
JCO Precis Oncol. 2022 Mar;6:e2100181. (PMID: 35263168)
Hum Genomics. 2023 Oct 28;17(1):96. (PMID: 37898819)
JAMA Netw Open. 2024 Jan 2;7(1):e2351700. (PMID: 38252441)
JCO Precis Oncol. 2024 Jan;8:e2300382. (PMID: 38166232)
JCO Oncol Pract. 2024 Nov;20(11):1481-1490. (PMID: 39531845)
Nature. 2023 Jul;619(7969):259-268. (PMID: 37438589)
JCO Oncol Pract. 2024 Nov;20(11):1508-1514. (PMID: 39531847)
J Clin Oncol. 2024 Aug 10;42(23):2736-2740. (PMID: 38754043)

Keywords: MRD; ctDNA; liquid biopsy

0 (Circulating Tumor DNA)
0 (Biomarkers, Tumor)

Date Created: 20250312 Date Completed: 20250312 Latest Revision: 20250314

20250314

PMC11897061

10.1111/cts.70185

40070025